Abaloparatide new option for osteoporosis treatment

A new osteoporosis drug treatment called abaloparatide is set to be recommended for postmenopausal women by The National Institute for Health and Care Excellence (NICE).
Abaloparatide, which is an anabolic drug, works in a slightly different way to many other drug treatments as it stimulates bone formation. This helps strengthen bones, making them less likely to break.
The treatment is similar to teriparatide and will bring additional drug treatment options to people who have a very high fracture risk. Available to patients in the US for the treatment of osteoporosis since 2017, abaloparatide is now licenced in the UK.
Prof Emma Clark from the Royal Osteoporosis Society comments:
“Having an additional anabolic medication to help people at the highest risk of fractures is good news. It has the potential to bring relief and hope to many women at higher fracture risk, and we hope that in the future it will be available for men too.”

PS Did you know that Arthritis Digest Magazine is labelled the best UK Arthritis blog from thousands of blogs on the web ranked by traffic, social media followers, domain authority & freshness?